Clinical Trial Update: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing safety, tolerability, and immunogenicity of V114 in healthy infants; results completed with posted findings in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• V114 (15-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2022-03-25